The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma

Shi, Z.; Zhao, Yunfeng; Zhang, Ming-zhou; Wu, Xueling

doi:10.1111/crj.12362

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zhang et al konnten in einer aktuellen Arbeit zwar nachweisen, dass die Sensitivität und Sensibilität von Tumormarkern bei Diagnostik peripherer Lungenherde durch Bronchiallavage deutlich höher als bei Bestimmung der Serumspiegel der entsprechenden Marker liegt. Für den klinischen Alltag sind die erhobenen Sensitivitätswerte von maximal 84 % (erreicht über eine Bestimmung von HSP 90 α in der BAL) jedoch nicht ausreichend [10].…”

Section: Resultsunclassified

Evaluation zum möglichen Stellenwert der Bronchiallavagezytologie bei Erstdiagnose und Nachsorge des Lungenkarzinoms

Grünewaldt

Hügel

Hermann³

et al. 2017

Pneumologie

View full text Add to dashboard Cite

Bronchoalveolar lavage [BAL] is an important procedure in the diagnosis of a variety of lung diseases. While it has enormous value in the diagnostics of inflammatory parenchymal diseases, its significance in lung cancer is unclear. Keeping in mind that immune therapy (e. g. application of checkpoint inhibitors) is gaining importance in the management of lung carcinoma, it is important to know if there are typical cellular patterns in BAL of lung cancer patients. In a retrospective proof of principle-study, we analyzed 38 patients who underwent BAL at the initial diagnosis of lung cancer. We observed an elevated level of CD25 lymphocytes as well as an increased expression of DR antigen, both signaling lymphocyte activation. We could not find a typical cytologic pattern of inflammatory cells in lung carcinoma patients. Sensitivity of BAL to malignant cells was rare, thus confirming earlier analysis. We could not demonstrate typical cellular patterns in BAL of lung cancer patients. Evaluation of specific microRNA patterns might play a supporting role in the initial diagnosis as well as follow-up of lung cancer patients.

show abstract

Section: Resultsunclassified

Evaluation zum möglichen Stellenwert der Bronchiallavagezytologie bei Erstdiagnose und Nachsorge des Lungenkarzinoms

Grünewaldt

Hügel

Hermann³

et al. 2017

Pneumologie

View full text Add to dashboard Cite

show abstract

“…These studies suggested that HSP90α maybe also a potential biomarker in LC. Zhang et al 21 found the diagnostic value of HSP90α for peripheral LC in bronchoalveolar lavage fluid. The same results were also obtained in our study, the results of plasma level of HSP90α also had a higher level compared with HC in LC patients, even in early‐stage patients, and not affected by the gender and age.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of HSP90α and related markers in lung cancer

Yuan

Wang

Hong³

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Purpose To investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer (LC) and the clinical value of HSP90α and other related markers in the diagnosis of LC. Methods Of 335 patients enrolled in the study cohort, 175 were screened for LC and 160 were healthy (HC). The plasma levels of HSP90α and related markers (CEA, NSE, CYFRA21‐1 and ProGRP) were detected in all individuals in the cohort by enzyme‐linked immunosorbent assay (ELISA). Groups were divided according to gender (male/female), age (≤60 years/>60 years), types of LC (small‐cell carcinoma, squamous carcinoma and adenocarcinoma), staging (I, II, III and IV) and metastasis (metastasis and non‐metastasis) separately. Wilcoxon Mann–Whitney test and Kruskal–Wallis test were used to compare statistical differences between two groups/among the multiple groups for each factor of HSP90α. The r ‐value and Kappa were used to compare HSP90α with related markers, and the receiver operating curve (ROC) was used to evaluate the efficacy of plasma HSP90α in predicting LC. Results No statistical difference was found in the plasma level of HSP90α among different age and gender groups ( p > 0.05). In the group divided by LC type, staging and metastasis status, there were statistical differences among different groups in HSP90α level ( p < 0.05). The levels of HSP90α, CEA, NSE, CYFRA21‐1 and ProGRP in LC groups were significantly higher than HC ( p < 0.001). R values of HSP90α correlated with other related markers in the diagnosis of LC ( p < 0.05). Although HSP90α and other related markers did not fit the satisfactory conformance, in terms of the positive rate of diagnosis, it was statistically differences in the diagnostic positive rate between HSP90α and each marker ( p < 0.01). ROC analysis showed that a plasma HSP90α cut‐off point of 50.02 ng/ml had an optimal predictive value for LC. Conclusions HSP90α has significant clinical value in early screening and diagnosis of LC. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of LC effectively.

show abstract

“…Tumor markers have become an important auxiliary tool for clinical diagnosis 54 . It has been reported that CA19-9 has high accuracy and detection efficiency as a tumor marker for the diagnosis of pancreatic cancer and liver cancer 55,56 .…”

Section: Discussionmentioning

confidence: 99%

Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Wang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.

show abstract

The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma

Abstract: Detection of tumor markers in BALF was superior to serum specimens. The measurement of USP8, HSP90α and YKL40 in BALF had more clinical value for the diagnosis of peripheral pulmonary carcinoma.

Cited by 9 publications

References 27 publications

Evaluation zum möglichen Stellenwert der Bronchiallavagezytologie bei Erstdiagnose und Nachsorge des Lungenkarzinoms

Evaluation zum möglichen Stellenwert der Bronchiallavagezytologie bei Erstdiagnose und Nachsorge des Lungenkarzinoms

Diagnostic value of HSP90α and related markers in lung cancer

Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Contact Info

Product

Resources

About